Reifs, Carmen María AlcántaraSalido-Vallejo, RafaelGarnacho-Saucedo, Gloria MaríaCorte-Sánchez, Sofía De laGonzález-Menchen, AlbertoGarcía-Nieto, Antonio Vélez2023-01-252023-01-252016http://hdl.handle.net/10668/10596Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/AgedAlemtuzumabAntibodies, Monoclonal, HumanizedAntigens, Differentiation, T-LymphocyteAntineoplastic AgentsBlood Cell CountHumansMaleSezary SyndromeSkin NeoplasmsTreatment Outcomeresearch article27828640open access10.1590/abd1806-4841.201643221806-4841PMC5087225http://www.scielo.br/pdf/abd/v91n5/0365-0596-abd-91-05-0642.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087225/pdf